NCT02634983View on ClinicalTrials.gov

QVA Mechanistic Efficacy Study (Receptor Effects, Etc)

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

September 26, 2017

Study Completion Date

September 26, 2017

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

QVA149

QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.

DRUG

Placebo

Matching placebo

Trial Locations (3)

S10 2JF

Novartis Investigative Site, Sheffield

BD9 6RJ

Novartis Investigative Site, Bradford

M23 9QZ

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY